**Supplemental online material**

**Main inclusion criteria:** provided written informed consent; Caucasian (defined as white European) males aged 30 to 65 years at screening; body weight of ≥60 kg; body mass index ranging from 18.0 to 32.0 kg/m2 at screening and Day −1; normal ECG measurements defined as a heart rate between 50 and 100 beats per minute at screening, Day −1 and pre-dose; vital signs within the following ranges at screening and Day −1: body temperature: 35.0–37.5°C; systolic blood pressure: 90–140 mmHg, diastolic blood pressure: 50–90 mmHg; Holter recording with no clinically significant abnormalities; ectopic beat rate of <0.5% of total beats and no second degree or higher atrioventricular block-related findings (occasional nocturnal Mobitz type 1 atrioventricular block was acceptable) at screening; and regular daily bowel movements.

**Main exclusion criteria:** presence or history of severe adverse reaction or allergy to any medicinal product of clinical significance; participated in more than three clinical studies of a new chemical entity in the previous year; radiation exposure exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years; any prescribed systemic or topical medication within 14 days of dose administration; any non-prescribed systemic or topical medication (including herbal remedies and vitamin/mineral supplements) within 7 days of dose administration; clinically significant endocrine, thyroid, hepatic, respiratory, gastrointestinal or renal disease, diabetes mellitus, coronary heart disease, hypertension, eye disorders, or history (in the last 2 years) of any psychiatric/psychotic disorder; clinically relevant abnormal medical history, physical findings, or laboratory values at screening and/or Day −1 that could interfere with the objectives of the study; positive hepatitis B surface antigen, hepatitis C virus antibody, or HIV, or a negative Herpes Zoster/Varicella immunoglobulin-G test result at screening; clinically significant 12-lead ECG abnormalities (except occasional nocturnal Mobitz type 1 atrioventricular block); any surgical or medical condition that might have significantly altered the absorption, distribution, metabolism or excretion of drugs; use of tobacco/nicotine-containing products within 3 months before administration of the study drug through to the final study visit; or previous exposure to MT-1303.